Division of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital, No. 123, Dapi Rd, Niaosong Dist., Kaohsiung, 833, Taiwan (ROC).
Kaohsiung Breast Cancer Prevention and Education Society, 10B, No. 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan (ROC).
Breast Cancer Res Treat. 2018 Aug;170(3):583-591. doi: 10.1007/s10549-018-4778-y. Epub 2018 Apr 5.
The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer.
This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer.
The survival rate at 24 months was 57.2% (95% CI 51.0-62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45-3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients' tumors with the luminal A subtype had a significantly better objective response rate. Kaplan-Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events.
Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.
本研究旨在确认艾立布林对台湾转移性乳腺癌女性患者的治疗作用。
本回顾性研究纳入了 2014 年 3 月至 2017 年 6 月间在台湾 14 家医院接受艾立布林治疗局部晚期或转移性乳腺癌的 449 名女性患者。
24 个月的生存率为 57.2%（95%CI：51.0-62.9%），中位无进展生存期（TTF）为 3.91 个月（95%CI：3.45-3.94）。共有 175 名患者（40.1%）接受艾立布林治疗的时间少于 90 天，其余患者接受的治疗时间为 90 天或更长。8 名患者（1.83%）达到完全缓解，82 名患者（18.8%）达到部分缓解，202 名患者（46.3%）病情稳定，144 名患者（33.0%）病情进展。具有 luminal A 亚型的肿瘤患者客观缓解率明显更高。Kaplan-Meier 分析表明，激素受体阳性、luminal A 亚型、艾立布林作为一线至三线治疗药物、转移至<4 个器官与更长的 TTF 显著相关。多因素逐步分析显示，仅艾立布林作为一线至三线治疗药物与 TTF 显著相关（HR 1.49，p<0.001）。所有毒性反应均可控制，仅有 18 名患者（4.1%）因不良反应而停止治疗。
与西方女性相比，艾立布林在台湾女性中似乎具有更好的疗效，且引起的不良反应更少，特别是中性粒细胞减少症。
